| Bioactivity | BRD3308 is a highly selective HDAC3 inhibitor with an IC50 of 54 nM. BRD3308 is 23-fold selectivity for HDAC3 over HDAC1 (IC50 of 1.26 μM) or HDAC2 (IC50 of 1.34 μM). BRD3308 suppresses pancreatic β-cell apoptosis induced by inflammatory cytokines or glucolipotoxic stress, and increases functional insulin release. BRD3308 activates HIV-1 transcription and disrupts HIV-1 latency[1][2][3]. | ||||||||||||
| Invitro | BRD3308 (5-30 µM; 6-24 hours) treatment increases HIV-1 expression in the 2D10 cell line[1].BRD3308 (15 µM; overnight) is able to induce outgrowth of HIV-1 from latently infected cells ex vivo in resting CD4+ T cells[1].BRD3308 inhibits HDAC1, HDAC2 and HDAC3 with Ki values of 5.1 μM, 6.3 μM and 29 nM, respectively[3]. RT-PCR[1] Cell Line: | ||||||||||||
| Name | BRD3308 | ||||||||||||
| CAS | 1550053-02-5 | ||||||||||||
| Formula | C15H14FN3O2 | ||||||||||||
| Molar Mass | 287.29 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
BRD3308
CAS: 1550053-02-5 F: C15H14FN3O2 W: 287.29
BRD3308 is a highly selective HDAC3 inhibitor with an IC50 of 54 nM. BRD3308 is 23-fold selectivity for HDAC3 over HDAC1
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.